Media and briefings
Latest posts
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents ...
Read More
Read More
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents ...
Read More
Read More
Prescient Therapeutics: PTX-100 Phase 2 coming soon
Prescient Therapeutics update report 2024 08 29 ...
Read More
Read More
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr ...
Read More
Read More
Prescient Therapeutics: Current Developments in Cancer Treatment
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific ...
Read More
Read More
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics
WEBCAST AND MEDIA
Prescient Therapeutics (ASX: PTX) Investor Q&A - 25 March 2024
Pitt Street Research Briefing on Prescient Therapeutics - 14 March 2024
Prescient Therapeutics: PTX-100 targeted cell therapy briefing - 18 December 2023
Pitt Street Research Briefing on Prescient Therapeutics - 22 November 2023
Prescient Therapeutics (ASX: PTX) Investor Q&A - 8 November 2023
Prescient Therapeutics TechKnow Invest Roadshow - 2 August 2023
Prescient Therapeutics: Cell Therapies presentations from ISCT - 8th June 2023
Prescient Therapeutics Meeting on the Med Conference - April 2023
Prescient Therapeutics: PTX-100 targeted cell therapy briefing - 2nd March 2023
Prescient Therapeutics CellPryme-A Briefing - 27 September 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 10 June 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 3 March 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 19 October 2021
Prescient Therapeutics & Peter MacCallum Collaboration Update
Prescient Therapeutics with Special Guest Professor Miles Prince
Steven Yatomi Clarke on Stocks Down Under
ARTICLES
Follow us and stay connected
